Compare Abbott Laboratories (ABT) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.1 (market cap $143.90B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| ABT | BBVA | |
|---|---|---|
Market Cap | $166.94B | $143.90B |
Sector | Health | Financials |
52-Week High | $136.62 | $26.14 |
52-Week Low | $82.57 | $14.73 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BBVA trades at $26.07, up 1.84% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.51% net income margin and 18.67% ROE, while recent Q1 2026 earnings beat expectations. Positive sentiment is driven by analyst upgrades and news highlighting European bank outperformance and strategic partnerships, though regulatory scrutiny in Spain presents a headwind.
The outlook remains favorable given solid earnings growth, high ROE, and a majority analyst buy rating. Key risks include antitrust investigations and volatile cash flows, but the stock's reasonable P/E of 12.61 and dividend yield offer value. Upside is contingent on sustained loan growth and execution in key markets like Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
